Art. -Nr.: HY-125374

Larotaxel

Name: Larotaxel
Brand: MedChemExpress
SKU: HY-125374
Price: 150.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: XRP9881)

Kundenbewertung

Based on 1 Customer Validation

Larotaxel (XRP9881) is an orally active and blood-brain barrier penetrant Microtubule stabilizer with an IC₅₀ of 0.21 μM. Larotaxel shows activity in Taxane-resistant tumor models. Larotaxel exhibits antitumor activity in intracranial glioblastoma models. Larotaxel can be used for research on advanced solid tumors.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.50%
CAS. Nr.: 156294-36-9
Formel: C₄₅H₅₃NO₁₄
Molecular Weight:831.90

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Larotaxel Chemical Structure

CAS. Nr.: 156294-36-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	101.4 nM Compound: Larotaxel	Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
A549	IC₅₀	12.1 nM Compound: Larotaxel	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
KB	IC₅₀	15.8 nM Compound: Larotaxel	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
MCF7	IC₅₀	18.6 nM Compound: Larotaxel	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]
NCI/ADR-RES	IC₅₀	280.8 nM Compound: Larotaxel	Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay	[PMID: 30036834]

In Vitro

Larotaxel stabilizes microtubules in cell-free assays, preventing cold-induced depolymerization with an IC₅₀ of 0.21 μM^[1].
Larotaxel shows in vitro activity in various Taxane-resistant tumor models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Larotaxel exhibits significant antitumor activity in nude mice bearing early-stage intracranial glioblastoma^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 156294-36-9
Appearance Solid
Molecular Weight 831.90
Formel C₄₅H₅₃NO₁₄
Color White to off-white
SMILES

O=C([C@]1([H])OC(C)=O)[C@@]23[C@@]([C@@H]([C@@]4(O)C(C)(C)C1=C([C@H](OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C4)C)OC(C6=CC=CC=C6)=O)([H])[C@]7([C@@](OC7)([H])C[C@@H]2C3)OC(C)=O
Synonyms

XRP9881
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (60.10 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2021 mL

6.0103 mL

12.0207 mL

5 mM

0.2404 mL

1.2021 mL

2.4041 mL

10 mM

0.1202 mL

0.6010 mL

1.2021 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (298 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yamamoto N, et al. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer chemotherapy and pharmacology. 2009 Dec;65(1):129-36.

[2]. Men L, et al. Metabolism of TM-2, a potential antitumor drug, in rats by using LC-MS. Journal of separation science. 2014 Mar;37(6):625-9.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2021 mL	6.0103 mL	12.0207 mL	30.0517 mL
	5 mM	0.2404 mL	1.2021 mL	2.4041 mL	6.0103 mL
	10 mM	0.1202 mL	0.6010 mL	1.2021 mL	3.0052 mL
	15 mM	0.0801 mL	0.4007 mL	0.8014 mL	2.0034 mL
	20 mM	0.0601 mL	0.3005 mL	0.6010 mL	1.5026 mL
	25 mM	0.0481 mL	0.2404 mL	0.4808 mL	1.2021 mL
	30 mM	0.0401 mL	0.2003 mL	0.4007 mL	1.0017 mL
	40 mM	0.0301 mL	0.1503 mL	0.3005 mL	0.7513 mL
	50 mM	0.0240 mL	0.1202 mL	0.2404 mL	0.6010 mL
	60 mM	0.0200 mL	0.1002 mL	0.2003 mL	0.5009 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Larotaxel